Natera

Associate Director / Director, Signatera Emerging Indications

United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Biotechnology, Medical DiagnosticsIndustries

Requirements

The ideal candidate should possess a Bachelor’s degree in life sciences, with an advanced degree (MBA or PhD) preferred, and 8-10 years of experience in product marketing, field sales, or market analytics within the medical diagnostics, pharmaceutical, or biotech industry. Strong background in oncology and/or genomics is highly preferred, and familiarity with FDA-approved treatments for solid tumors is desirable. The role requires approximately 30% travel for advisory boards, industry congresses, field engagement, and marketing events.

Responsibilities

This Associate Director / Director will be responsible for developing and executing comprehensive marketing plans for the Signatera™ molecular residual disease (MRD) test in emerging oncology indications, including sarcoma, melanoma, and head & neck cancers. They will track and assess product sales performance, manage the development of marketing materials and digital content, oversee speaker bureau content, identify and manage partnerships, serve as a subject matter partner across various teams, and contribute to broader strategic initiatives supporting portfolio growth and MRD market expansion. They will also perform other duties as assigned.

Skills

Product Marketing
Market Analytics
Digital Content Development
Sales Collateral
Partnership Management
Cross-functional Collaboration
Strategic Planning
Medical Diagnostics
Biotech Industry Knowledge

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI